Avalo Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Avalo Therapeutics is Garry Neil, benoemd in Feb2022, heeft een ambtstermijn van 2.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.08M, bestaande uit 44.2% salaris en 55.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.001% van de aandelen van het bedrijf, ter waarde € 563.95. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 2.7 jaar.

Belangrijke informatie

Garry Neil

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	44.2%
Dienstverband CEO	2.8yrs
Eigendom CEO	0.0006%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	2.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Garry Neil's beloning veranderd ten opzichte van Avalo Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$19m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$1m	US$475k	-US$32m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$25m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$1m	US$469k	-US$42m
Sep 30 2022	n/a	n/a	-US$51m
Jun 30 2022	n/a	n/a	-US$72m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$1m	US$423k	-US$84m
Sep 30 2021	n/a	n/a	-US$81m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$73m
Dec 31 2020	US$3m	US$373k	-US$64m

Compensatie versus markt: De totale vergoeding ($USD 1.08M ) Garry } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 476.59K ).

Compensatie versus inkomsten: De vergoeding van Garry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Garry Neil (70 yo)

2.8yrs

Tenure

US$1,075,362

Compensatie

Dr. Garry A. Neil, M.D., serves as the Member of Scientific Advisory Board of Rapafusyn Research And Development, Inc. Dr. Garry serves as Independent Director of Celldex Therapeutics, Inc. since June 16,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Garry Neil	Chairman of the Board	2.8yrs	US$1.08m	0.00057% € 564.0
Christopher Sullivan	CFO & Head of Investor relations	2.8yrs	US$607.65k	0.000060% € 59.4
Solomon Snyder	Founder and Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Barbara Slusher	Founder and Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Paul Varki	Chief Legal Officer	less than a year	geen gegevens	geen gegevens
Lisa Hegg	Senior Vice President of Program Management	2.8yrs	geen gegevens	geen gegevens
Colleen Matkowski	Senior Vice President of Global Regulatory Affairs & Quality Assurance	2.8yrs	geen gegevens	geen gegevens
Dino Miano	Senior Vice President of CMC & Technical Operations	2.8yrs	geen gegevens	geen gegevens
Mittie Doyle	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van C6K0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Garry Neil	Chairman of the Board	2.4yrs	US$1.08m	0.00057% € 564.0
Solomon Snyder	Founder and Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Barbara Slusher	Founder and Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Sol Barer	Special Advisor & Strategic Advisory Board	3.4yrs	US$133.94k	geen gegevens
Gilla Kaplan	Independent Director	4.1yrs	US$60.12k	0% € 0
Ronald Borchardt	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Robert Lenox	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Anne Young	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dennis Liotta	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Aaron Kantoff	Independent Director	less than a year	geen gegevens	geen gegevens
Samantha Truex	Independent Director	less than a year	geen gegevens	geen gegevens
Mitchell Chan	Independent Director	2.9yrs	US$60.12k	0% € 0

2.7yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van C6K0 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.7 jaar), wat duidt op een nieuw bestuur.

Avalo Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer

Avalo Therapeutics, Inc., Annual General Meeting, Aug 13, 2024

Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer

Avalo Therapeutics, Inc. Announces Board Appointments

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Insider recently bought €52k worth of stock

Recent updates

Avalo Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Lotus Trial of Avtx-009 for the Treatment of Hidradenitis Suppurativa

Avalo Therapeutics, Inc. Appoints Mittie Doyle as Chief Medical Officer

Avalo Therapeutics Announces Active IND for AVTX-009, an Anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa

Avalo Therapeutics, Inc., Annual General Meeting, Aug 13, 2024

Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer

Avalo Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Stockholders' Equity Requirement

Avalo Therapeutics, Inc. Announces Board Appointments

Hearings Panel Grants Avalo Therapeutics an Exception from Compliance with the MVLS Rule and the Bid Price Rule and Extension of Continued Listing Until December 29, 2023

Avalo Therapeutics, Inc., Annual General Meeting, Dec 05, 2023

Nasdaq Determines to Delist Securities of Avalo Therapeutics

AUG Therapeutics, LLC entered into a purchase agreement to acquire rights, title and interest in, assets relating to AVTX-800 Series from Avalo Therapeutics, Inc. (NasdaqCM:AVTX).

Avalo Therapeutics, Inc. Receives Notice from Nasdaq Regarding Bid Price Rule

New major risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$1.38 loss in 2Q 2022)

New minor risk - Insider selling

New major risk - Revenue and earnings growth

Avalo Announces Topline Data from Phase 2 Peak Trial for Avtx-002 (Quisovalimab) in Patients with Non-Eosinophilic Asthma

Insider recently bought €52k worth of stock

Insider recently bought €83k worth of stock

Insider recently bought €63k worth of stock

First quarter 2023 earnings released: US$0.85 loss per share (vs US$2.35 loss in 1Q 2022)

Insider recently bought €49k worth of stock

Insider recently bought €131k worth of stock

Full year 2022 earnings released

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering.

Avalo Therapeutics, Inc. Completes Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

High number of new and inexperienced directors

Forecast to breakeven in 2024

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$2.04 loss in 3Q 2021)

High number of new and inexperienced directors

Avalo Therapeutics, Inc. Advances B and T Lymphocyte Attenuator Agonist Fusion Protein (AVTX-008) to IND-Enabling Stage

Avalo Therapeutics Announces Board Changes

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Avalo Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021)

Avalo Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Avalo Therapeutics, Inc. Announces Executive and Board Changes

Avalo Therapeutics, Inc. Announces Chief Executive Officer Changes

Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer

Avalo Therapeutics, Inc. Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2020)

Avalo Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $27.5 million.

Avalo Therapeutics, Inc.(NasdaqCM:AVTX) dropped from NASDAQ Composite Index

Second quarter 2021 earnings released: US$0.88 loss per share (vs US$0.19 loss in 2Q 2020)

High number of new directors

Cerecor Inc. announced that it expects to receive $35 million in funding from Horizon Technology Finance Management, LLC

First quarter 2021 earnings released: US$0.32 loss per share (vs US$0.36 loss in 1Q 2020)

Forecast to breakeven in 2024

U.S. Food and Drug Administration Grants Fast Track Designation to CERC-002 of Cerecor Inc. for Treatment of Hospitalized Patients with COVID-19

Cerecor Inc. Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease

Full year 2020 earnings released: US$0.88 loss per share (vs US$0.28 loss in FY 2019)

Revenue beats expectations

Cerecor Inc. Announces Final Efficacy Data Including 60-Day Mortality from Their Recently Completed Us-Based, Multi-Center (10 Sites)

Cerecor Inc. Appoints Schond L. Greenway as Chief Financial Officer

New 90-day high: €3.56

New 90-day high: €3.16

Cerecor Announces Fast Track Designation for CERC-803 for the Treatment of Leukocyte Adhesion Deficiency Type II

New 90-day high: €2.72

Cerecor Inc. Announces Successful Proof of Concept Data for CERC-002, a Unique LIGHT-Neutralizing Antibody, in Patients Hospitalized with COVID-19 ARDS

New 90-day high: €2.26

Cerecor Inc. Announces First Patient Dosed in A Phase 1B Clinical Trial of Cerc-007 for the Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma

Cerecor Inc. Enters into an Amendment to Its Existing License and Supply Agreement with Watson Laboratories, Inc

Cerecor Inc. Appoints Gilla Kaplan, to Its Board of Directors

Cerecor Inc. Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

Analyse CEO-vergoeding